Function & Composition of Regulatory B Cells in Participants With

Status Recruiting

Clinical Trial Summary

Rationale: This project elaborates on a novel finding of the investigators that has not yet been reported in literature, namely the presence of elevated levels of atypical B cells in participants with glioblastoma. ln the period 2015 2018 the investigators analysed the blood immune subset composition of a cohort of 180 participants undergoing neurosurgery. The most relevant finding was the presence of an abnormally elevated level of B cells in the blood of the great majority of participants with glioblastoma. These B cells may be involved in the immunosuppression associated with glioblastoma that makes this tumor refractory to immunotherapy. Multiple regression analysis indicated that the increase in the frequency of atypical B cells in participants' peripheral blood was related with the administration of dexamethasone prior to surgery. However, this study design did not allow the investigators to address the causality of the relationship between dexamethasone and atypic B cell dysregulation. Alternative treatments to dexamethasone exist. Objective: To investigate the effect of dexamethasone in the dysregulation of atypic B cells in participants with glioblastoma. Study design: Observational case control pilot study with 20 participants (10 per group). Study population: Newly diagnosed participants with glioblastoma. Intervention (if applicable): Observational study. Main study parameters/endpoints: Changes in the immune subset composition and functionality in the peripheral blood of participants with glioblastoma upon administration of dexamethasone for neurological signs of peritumoral edema (oral dexamethasone). Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The investigators will collect blood (28 ml) during the first visit and again (28 ml) at the time of surgery (2 weeks ± 3 days). There will not be additional site visits, physical examinations or any other tests, questionnaires. Blood collection is only a minor discomfort and it does not represent any additional risk.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04128774
Study type	Observational
Source	VU University Medical Center
Contact	Mathilde CM Kouwenhoven, MD, PhD
Phone	+31 20 4444444
Email	m.kouwenhoven@amsterdamumc.nl
Status	Recruiting
Phase
Start date	January 1, 2021
Completion date	November 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03291977` - Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)	Phase 3
Active, not recruiting	`NCT03665545` - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma	Phase 1/Phase 2
Terminated	`NCT03714334` - DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma	Phase 1
Recruiting	`NCT03277638` - Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)	Phase 1/Phase 2
Completed	`NCT03158389` - NCT Neuro Master Match - N²M² (NOA-20)	Phase 1/Phase 2
Completed	`NCT03522298` - Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma	Phase 2
Recruiting	`NCT03213002` - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM	Phase 1/Phase 2
Completed	`NCT03232424` - NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma	Phase 1
Active, not recruiting	`NCT04116658` - First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Phase 1/Phase 2
Completed	`NCT03618667` - GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification	Phase 2
Completed	`NCT03744026` - Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9	Phase 1/Phase 2
Completed	`NCT04610229` - Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.	N/A
Active, not recruiting	`NCT02974738` - A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)	Phase 1
Recruiting	`NCT03025893` - A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme	Phase 2/Phase 3
Active, not recruiting	`NCT03181477` - Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas	N/A
Completed	`NCT03075514` - Ketogenic Diets as an Adjuvant Therapy in Glioblastoma	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Function and Composition of Regulatory B Cells in Participants With Glioblastoma — GBMdexaB

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms